[
  {
    "ts": null,
    "headline": "Revvity price target lowered to $110 from $120 at Stifel",
    "summary": "Stifel lowered the firm’s price target on Revvity (RVTY) to $110 from $120 and keeps a Hold rating on the shares. Q2 performances in most business areas were inline with expectations, but new pressures in China for the ImmunoDx business have growth stepping down and pressure the overall outlook for the year, the analyst tells investors in a post-earnings note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks",
    "url": "https://finnhub.io/api/news?id=0ffc2acd711fd2be9a7c04b695437db178ff041d910719961115d4430453556d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753881914,
      "headline": "Revvity price target lowered to $110 from $120 at Stifel",
      "id": 136130862,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "RVTY",
      "source": "Yahoo",
      "summary": "Stifel lowered the firm’s price target on Revvity (RVTY) to $110 from $120 and keeps a Hold rating on the shares. Q2 performances in most business areas were inline with expectations, but new pressures in China for the ImmunoDx business have growth stepping down and pressure the overall outlook for the year, the analyst tells investors in a post-earnings note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks",
      "url": "https://finnhub.io/api/news?id=0ffc2acd711fd2be9a7c04b695437db178ff041d910719961115d4430453556d"
    }
  }
]